Upgrade to SI Premium - Free Trial

Sapiens Reports Third Quarter 2021 Financial Results

November 3, 2021 7:00 AM

HOLON, Israel, Nov. 3, 2021 /PRNewswire/ -- Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the third quarter ended September 30, 2021.

Sapiens International Corporation Logo

Summary Results for Third Quarter 2021 (USD in millions, except per share data)

GAAP

Non-GAAP

September 30, 2021

September 30, 2020

% Change

September 30, 2021

September 30, 2020

% Change

Revenue

$117.8

$97.6

20.7%

$118.4

$98.0

20.9%

Gross Profit

$48.3

$40.1

20.5%

$53.4

$44.2

20.8%

Gross Margin

41.0%

41.0%

-

45.1%

45.1%

-

Operating Income

$16.2

$12.1

34.1%

$21.0

$17.9

17.7%

Operating Margin

13.8%

12.4%

140 bps

17.7%

18.2%

(50) bps

Net Income (*)

$13.3

$9.3

42.1%

$17.0

$13.7

23.5%

Diluted EPS

$0.24

$0.18

33.3%

$0.31

$0.27

14.8%

(*) Attributable to Sapiens' shareholders

"Revenue in the third quarter increased by 21% year-over-year, reaching a non-GAAP quarterly record of $118.4 million, and non-GAAP operating profit increased to a record $21.0 million for an operating margin of 17.7%," stated Roni Al-Dor, President and CEO of Sapiens.

"We continue to reinforce Sapiens' leadership position in the evolving insurance software industry, across all tiers, both in P&C and Life & Annuities/Pension. We are landing new business and expanding by upselling and cross-selling to existing customers, while focusing on further advancing our product offerings and our commitment to customer success. The solid results we achieved in the third quarter were the direct outcome of successfully executing our strategy and our commitment to achieving consistent growth and improving operating margin," continued Mr. Al-Dor.

"We are reiterating our 2021 non-GAAP revenue guidance of $461 million to $466 million, expecting to reach approximately the midpoint of the range, and increasing our annual non-GAAP operating margin from 17.2%-17.5% to the range of 17.4%-17.5%," concluded Mr. Al-Dor.

Quarterly Results Conference CallManagement will host a conference call and webcast today, November 3, 2021 at 9:30 am. Eastern Time (3:30 pm. in Israel) to review and discuss Sapiens' results.

Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

North America (toll-free): + 1-888-642-5032; International: +972-3-918-0609; UK: 0-800-917-5108

The live webcast of the call can be viewed on Sapiens' website at: https://www.sapiens.com/investor-relations/ir-events-presentations. A replay of the call will be available one business day following the completion of the event, at the same link for 90 days.

Non-GAAP Financial Measures

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens' financial condition and results of operations. The Company's management uses these non-GAAP measures to compare the Company's performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company's board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company's financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company's financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company's business.

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

The Company defines Adjusted EBITDA as net profit, adjusted for valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalized of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies to help investors understand the operational performance of their business.

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

About Sapiens

Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative and agile. Backed by more than 35 years of industry expertise, Sapiens offers a complete insurance platform, with pre-integrated, low-code solutions and a cloud-first approach that accelerates customers' digital transformation. Serving over 600 customers in 30 countries, Sapiens offers insurers across property and casualty, workers compensation and life markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management. For more information visit www.sapiens.com or follow us on LinkedIn.

Media Contact

Shay AssarafChief Marketing Officer, Sapiens[email protected]

Investors Contact

Brett MaasManaging Partner, Hayden IR+1 646-536-7331[email protected]

Kimberly RogersManaging Director, Hayden IR+1 541-904-5075[email protected]

Forward Looking Statements

Certain matters discussed in this press release that are incorporated herein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words "anticipate," "believe," "estimate," "expect," "may," "will," "plan" and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers' systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company. While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF INCOME U.S. dollars in thousands (except per share amounts)

Three months ended

Nine months ended

September 30

September 30

2021

2020

2021

2020

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Revenue

117,812

97,645

341,810

281,242

Cost of revenue

69,512

57,567

202,630

166,641

Gross profit

48,300

40,078

139,180

114,601

Operating expenses:

Research and development, net

13,767

10,375

40,122

30,229

Selling, marketing, general and administrative

18,316

17,606

57,302

49,594

Total operating expenses

32,083

27,981

97,424

79,823

Operating income

16,217

12,097

41,756

34,778

Financial and other expenses (income), net

(72)

1,042

512

2,593

Taxes on income

2,923

1,520

7,560

6,430

Net income

13,366

9,535

33,684

25,755

Attributable to non-controlling interest

97

196

177

299

Net income attributable to Sapiens' shareholders

13,269

9,339

33,507

25,456

Basic earnings per share

0.24

0.19

0.61

0.51

Diluted earnings per share

0.24

0.18

0.60

0.50

Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)

54,787

50,625

54,732

50,367

Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)

55,611

51,581

55,564

51,280

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

RECONCILIATION OF GAAP TO NON-GAAP RESULTSU.S. dollars in thousands (except per share amounts)

Three months ended

Nine months ended

September 30,

September 30,

2021

2020

2021

2020

(unaudited)

(unaudited)

(unaudited)

(unaudited)

GAAP revenue

117,812

97,645

341,810

281,242

Valuation adjustment on acquired deferred revenue

630

323

1,889

323

Non-GAAP revenue

118,442

97,968

343,699

281,565

GAAP gross profit

48,300

40,078

139,180

114,601

Revenue adjustment

630

323

1,889

323

Amortization of capitalized software

1,920

1,600

5,595

4,627

Amortization of other intangible assets

2,563

2,205

7,697

6,346

Non-GAAP gross profit

53,413

44,206

154,361

125,897

GAAP operating income

16,217

12,097

41,756

34,778

Gross profit adjustments

5,113

4,128

15,181

11,296

Capitalization of software development

(2,064)

(1,506)

(5,655)

(4,194)

Amortization of other intangible assets

1,342

825

4,066

2,112

Stock-based compensation

657

1,361

3,527

2,747

Acquisition-related costs (*)

(246)

954

938

2,517

Non-GAAP operating income

21,019

17,859

59,813

49,256

GAAP net income attributable to Sapiens' shareholders

13,269

9,339

33,507

25,456

Operating income adjustments

4,802

5,762

18,057

14,478

Tax effect on NON-GAAP adjustment

(1,095)

(1,355)

(3,707)

(2,436)

Non-GAAP net income attributable to Sapiens' shareholders

16,976

13,746

47,857

37,498

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as tax, accounting and legal rendered until the acquisition date.

Adjusted EBITDA Calculation U.S. dollars in thousands

Three months ended

Nine months ended

September 30

September 30

2021

2020

2021

2020

GAAP operating profit

16,217

12,097

41,756

34,778

Non-GAAP adjustments:

Valuation adjustment on acquired deferred revenue

630

323

1,889

323

Amortization of capitalized software

1,920

1,600

5,595

4,627

Amortization of other intangible assets

3,905

3,030

11,763

8,458

Capitalization of software development

(2,064)

(1,506)

(5,655)

(4,194)

Stock-based compensation

657

1,361

3,527

2,747

Compensation related to acquisition and acquisition-related costs

(246)

954

938

2,517

Non-GAAP operating profit

21,019

17,859

59,813

49,256

Depreciation

1,125

1,151

3,371

3,332

Adjusted EBITDA

22,144

19,010

63,184

52,588

Summary of NON-GAAP Financial Information U.S. dollars in thousands (except per share amounts)

Q3 2021

Q2 2021

Q1 2021

Q4 2020

Q3 2020

Revenues

118,442

115,036

110,222

102,936

97,968

Gross profit

53,413

51,720

49,229

47,044

44,206

Operating income

21,019

19,795

19,000

18,666

17,859

Net income to Sapiens' shareholders

16,976

15,975

14,908

14,461

13,746

Adjusted EBITDA

22,144

20,920

20,120

20,032

19,010

Basic earnings per share

0.31

0.29

0.27

0.27

0.27

Diluted earnings per share

0.31

0.29

0.27

0.27

0.27

Non-GAAP Revenues by Geographic Breakdown U.S. dollars in thousands

Q3 2021

Q2 2021

Q1 2021

Q4 2020

Q3 2020

North America

48,952

46,767

44,754

47,303

49,979

Europe

59,707

59,718

57,642

49,225

42,394

Rest of the World

9,783

8,551

7,826

6,408

5,595

Total

118,442

115,036

110,222

102,936

97,968

Adjusted Free Cash-FlowU.S. dollars in thousands

Q3 2021

Q2 2021

Q1 2021

Q4 2020

Q3 2020

Cash-flow from operating activities

14,556

26,845

11,755

21,030

16,705

Increase in capitalized software development costs

(2,064)

(1,959)

(1,632)

(1,604)

(1,506)

Capital expenditures

(1,082)

(1,082)

(821)

(725)

(963)

Free cash-flow

11,410

23,804

9,302

18,701

14,236

Cash payments attributed to acquisition-related costs(*) (**)

477

-

1,280

2,363

242

Adjusted free cash-flow

11,887

23,804

10,582

21,064

14,478

(*) Included in cash-flow from operating activities(**) Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETU.S. dollars in thousands

September 30,

December 31,

2021

2020

(unaudited)

(unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

144,714

152,561

Short-term bank deposit

40,000

30,000

Trade receivables, net and unbilled receivables

76,031

65,409

Other receivables and prepaid expenses

14,670

19,388

Total current assets

275,415

267,358

LONG-TERM ASSETS

Property and equipment, net

15,481

16,970

Severance pay fund

7,054

6,582

Goodwill and intangible assets, net

345,893

363,597

Operating lease right-of-use assets

48,356

54,390

Other long-term assets

7,685

5,264

Total long-term assets

424,469

446,803

TOTAL ASSETS

699,884

714,161

LIABILITIES AND EQUITY

CURRENT LIABILITIES

Trade payables

8,983

5,389

Current maturities of Series B Debentures

19,796

19,796

Accrued expenses and other liabilities

78,045

75,119

Current maturities of operating lease liabilities

10,973

9,924

Deferred revenue

33,634

34,548

Total current liabilities

151,431

144,776

LONG-TERM LIABILITIES

Series B Debentures, net of current maturities

78,956

98,676

Deferred tax liabilities

12,925

16,010

Other long-term liabilities

12,772

12,129

Long-term operating lease liabilities

42,958

48,773

Redeemable non-controlling interest

97

517

Accrued severance pay

9,980

9,586

Total long-term liabilities

157,688

185,691

EQUITY

390,765

383,694

TOTAL LIABILITIES AND EQUITY

699,884

714,161

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWU.S. dollars in thousands

For the nine months ended September 30,

2021

2020

(unaudited)

(unaudited)

Cash flows from operating activities:

Net income

33,684

25,755

Reconciliation of net income to net cash provided by operating activities:

Depreciation and amortization

20,729

16,417

Accretion of discount on Series B Debentures

76

91

Capital loss from sale of property and equipment

(60)

4

Stock-based compensation related to options issued to employees

3,527

2,747

Net changes in operating assets and liabilities, net of amount acquired:

Trade receivables, net and unbilled receivables

(14,673)

(10,225)

Deferred tax liabilities, net

(3,777)

(391)

Other operating assets

12,122

3,653

Trade payables

3,520

(778)

Other operating liabilities

(1,292)

(294)

Deferred revenues

(810)

(194)

Accrued severance pay, net

110

440

Net cash provided by operating activities

53,156

37,225

Cash flows from investing activities:

Purchase of property and equipment

(2,985)

(1,908)

Investment in deposits

(9,989)

(379)

Proceeds from sale of property and equipment

1,112

12

Proceeds from restricted deposit used for completed acquisition

-

22,890

Proceeds from (payments for) business acquisitions, net of cash acquired

831

(35,395)

Capitalized software development costs

(5,655)

(4,194)

Net cash used in investing activities

(16,686)

(18,974)

Cash flows from financing activities:

Proceeds from employee stock options exercised

1,028

4,919

Distribution of dividend

(20,255)

(7,044)

Repayment of Series B Debenture

(19,796)

(9,898)

Issuance of Series B Debentures, net of issuance expenses of $863

-

60,386

Receipt of short-term loan

-

20,000

Repayment of loan

-

(20,000)

Payment of contingent considerations

(926)

(538)

Acquisition of non-controlling interests

(990)

-

Dividend to non-controlling interest

(31)

-

Net cash provided by (used in) financing activities

(40,970)

47,825

Effect of exchange rate changes on cash and cash equivalents

(3,347)

(704)

Increase (decrease) in cash and cash equivalents

(7,847)

65,372

Cash and cash equivalents at the beginning of period

152,561

66,295

Cash and cash equivalents at the end of period

144,714

131,667

Debentures Covenants

As of September 30, 2021, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

Covenant 1

  • Target shareholders' equity (excluding non-controlling interest): above $120 million.
  • Actual shareholders' equity (excluding non-controlling interest) equal to $389 million.

Covenant 2

  • Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company's Series B Debentures) below 65%.
  • Actual ratio of net financial indebtedness to net capitalization equal to (27.21)%.

Covenant 3

  • Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
  • Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (1.00).

Cision View original content:https://www.prnewswire.com/news-releases/sapiens-reports-third-quarter-2021-financial-results-301415105.html

SOURCE Sapiens International Corporation

Categories

PRNewswire Press Releases

Next Articles